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Role of TGF- signaling in extracellular matrix production of cases with cardiovascular disease [1, 2]. Many studies
under high glucose conditions. suggest a key role for hyperglycemia in the pathogenesis
Background. Hyperglycemia has been shown to play an im- of these complications [3–6]. Indeed, elevated glucose isportant role in diabetic renal and vascular complications. Some
known to activate a variety of cells to stimulate extracel-studies show that high glucose may mediate diabetic complica-
lular matrix (ECM) synthesis, which has been shown totions by stimulating extracellular matrix (ECM) production.
We hypothesize that this may be mediated by activating trans- be mediated by stimulating transforming growth factor-
forming growth factor- (TGF-)/Smads signaling. (TGF-) production [7–14]. Furthermore, the patho-
Methods. Renal and vascular cells were cultured under high genic role of TGF- in diabetic renal and vascular com-
glucose conditions in the presence or absence of a neutralizing
plications is supported by the ability of blocking TGF-TGF- antibody and examined for activation of Smad signaling
using a neutralizing antibody or antisense strategies inand collagen production. The regulating role of Smad signaling
in high glucose–induced collagen synthesis was determined by experimental models of diabetes [15–17]. However, the
inducing overexpression of the inhibitory Smad7 in a stable intracellular signaling pathway whereby high glucose in-
Smad7-expressing tubular cell line. duces renal and vascular sclerosis in diabetes remains
Results. Activation of Smad signaling, as evidenced by unclear.Smad2 and Smad3 nuclear translocation and phosphorylation,
TGF- is known to stimulate ECM in various cellwas found in renal and vascular cells at 24 hours after high
types by activating its intracellular signaling pathway,glucose stimulation (up to 55% increased). This was associated
with de novo synthesis of collagen I at day 3 by all cell types. Smads [18–20]. After binding to the receptors, TGF-
High glucose–induced activation of Smad signaling and colla- activates both receptor-associated Smads (Smad2 and
gen synthesis were TGF-–dependent since these were associ- Smad3). Activated Smad2 and Smad3 heteroligomerizeated with a significant increase in TGF- production at 24
with the common partner Smad4 (Co-Smad) to form thehours (P  0.01) and were blocked by a neutralizing TGF-
complexes and translocate into the nucleus to regulateantibody. Importantly, overexpression of Smad7 resulted in
marked inhibition of high glucose–induced Smad2 and Smad3 target gene expression. Activation of the TGF- signal-
activation and type I collagen synthesis, suggesting that Smad ing pathway can also result in the expression of inhibitory
signaling is a key pathway in high glucose–mediated renal and Smads (I-Smads), including Smad6 and Smad7. These
vascular scarring.
I-Smads appear to act by specifically inhibiting Smad2Conclusion. High glucose acts by activating the TGF- de-
and Smad3 phosphorylation by blocking their access topendent Smad signaling pathway to stimulate collagen synthe-
sis by renal and vascular cells. Smad signaling plays a critical TGF- receptors via the negative-feedback loop [18–20].
role in regulating high-glucose–mediated diabetic renal and Although high glucose is known to stimulate ECM syn-
vascular complications. thesis in a variety of cell types, the role of TGF-/Smad
signaling in diabetic nephropathy and vascular disease
under high glucose conditions has not been fully under-
Diabetic nephropathy and vascular disease remain ma- stood. In this study, we examined whether high glucose
jor complications of diabetes, accounting for up to 40% can activate the Smad signaling pathway and determined
of cases with end-stage-renal disease (ESRD) and 75% if this was dependent on TGF-.
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Fig. 1. Immunocytochemistry demonstrates
that high glucose (HG) induces Smad2 nuclear
translocation in tubular epithelial cells (TECs),
mesangial cells (MCs), vascular smooth mus-
cle cells (VSMCs), and vascular endothelial cells
(VECs) via the transforming growth factor-
(TGF-)-dependent mechanism. Activation
of Smad signaling as evidenced by phosphory-
lated Smad2 (p-Smad2) nuclear location (dark
black nucleus) is found at 24 hours under high
glucose (35 mmol/L), but not in normal glu-
cose (NG) (5.5 mmol/L) conditions. Note that
high glucose–induced p-Smad2 nuclear trans-
location is inhibited by the addition of a
neutralizing TGF- antibody (5 g/mL). (A )
Immunohistochemical staining with the anti-p-
Smad2 antibody (Ab). (B ) Semiquantitative
data. Magnification 250. *P  0.05; **P 
0.01 compared to NG; P  0.05 compared
to the anti-TGF- antibody (Ab) or control
rabbit immunoglobulin G (IgG) treatment.
Data are expressed as the mean SD for four
independent experiments. Symbols are: ()
normal glucose; ( ) high glucose; ( ), high
glucose  IgG; and ( ) high glucose  anti-
body.
lished as previously described [21]. The stable trans- pressing NRK52E cell line was used. All cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM)/F12fected cells were selected in the presence of puromycin
(2 g/mL). Positive clones were confirmed by their abil- (Gibco, BRL, Gaithersburg, MD, USA) containing 0.5%
fetal bovine serum (FBS) in 6-well plastic plates ority to express Smad7 in the presence of Dox by Western
blot analysis using an antiflag M2 antibody (IBI, Eastman 8-chamber glass slides (Nunc, Naperville, CT, USA) at
37C. Cells were stimulated with d-glucose at normalKodak, Rochester, NY, USA). The clone S7-7 was used
in this study. (5.5 mmol/L) or high (35 mmol/L) levels for periods of
15, 30, 60 minutes and 12 and 24 hours for Smad2 and
Cell culture 3 detection and for periods of 1, 3, and 5 days for collagen
matrix measurement. d-mannitol (35 mmol/L) was usedFour cell lines, including normal rat kidney epithelial
cells (NRK52E), glomerular mesangial cells (1097), vas- as a control for osmolality. In addition, a rabbit anti-
TGF- neutralizing antibody and its isotype- and spe-cular smooth muscle cells (VSMCs), and human vascular
endothelial cells (VECs) (EA.hy926), were used in this cies-matched normal rabbit immunoglobulin G (IgG)
(5 g/mL, R&D Systems, Minneapolis, MN, USA) wasstudy. In addition, the stable, Dox-regulated Smad7 ex-
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added into the cells and cultured for periods as described (Zymed Laboratories, South San Francisco, CA, USA)
followed by rabbit antiphosphoserine antibody (Zymedabove to block TGF- function induced by high glucose.
To induce Smad7 expression, cells were treated with Dox Laboratories). Total Smad2 and GAPDH were used as
a protein loading control for p-Smad2 or collagen I,at an optimal concentration (2 g/mL) for 24 hours in
the medium containing normal glucose (5.5 mmol/L) respectively.
and then were cultured under high glucose (35 mmol/L)
Immunocytochemistryconditions. Levels of secreted TGF-1 within the me-
dium were measured by enzyme-linked immunosorbent To detect the activation of TGF- Smad signaling,
cells cultured in 8-chamber glass slides were stained withassay (ELISA) (R&D Systems). Each experiment was
repeated at least four times throughout the study. rabbit polyclonal antibodies to p-Smad2 (Upstate Bio-
technology) or Smad3 (Zymed Laboratories) using a
Reverse transcription-polymerase chain peroxidase antiperoxidase method as previously de-
reaction analysis scribed [21]. An irrelevant isotype rabbit IgG1 (R&D
Systems) was used as the negative control.Total RNA from cultured cells was isolated and re-
verse transcription-polymerase chain reaction (RT-PCR)
Quantitative analysiswas performed using the method described previously
[21]. Gene expression for collagen I was detected using Quantitative analysis of p-Smad2 nuclear transloca-
tion for cultured cells was determined as described pre-published primers [21]. All samples were subjected to
RT-PCR for housekeeping gene glyceraldehydes-3- viously [21]. The number of cells with nuclear staining
for p-Smad2 or Smad3 was counted at least 1000 cellsphosphate dehydrogenase (GAPDH) as a positive con-
trol and as an internal standard [21]. RT-PCR products under high power (400) in each well. All scoring was
performed blind on coded slides.were resolved on 1.5% agarose gels in 1  Tris-borate-
ethylenediaminetetraacetic acid (EDTA) (TBE) buffer,
Statistic analysisvisualized by ethidium bromide, photographed using a
gel 1000 ultraviolet documentation system (Bio-Rad, Data obtained from this study are expressed as the
mean SD and analyzed by one-way analysis of varianceHercules, CA, USA), and analyzed by densitometry.
(ANOVA) or by unpaired Student t test using GraphPad
Western blotting and immunoprecipitation Prism 3.0 (GraphPad Software, Inc., San Diego, CA,
USA).Cells grown in 6-well plates with normal, high glucose,
and d-mannitol in the presence or absence of a neutraliz-
ing TGF- antibody or Dox (2 g/mL) at various time
RESULTS
points were analyzed for the activation of TGF- Smad
High glucose activates Smad signaling by renal andsignaling and collagen I expression (Santa Cruz Biotech-
vascular cellsnology, Santa Cruz, CA, USA) by Western blotting as
described previously [21]. Since activated Smads consist First, we examined whether the TGF- Smad signaling
pathway is activated in renal and vascular cells underof the phosphorylated Smad2 and Smad3, thus, activa-
tion of TGF- Smad signaling can be determined with high glucose conditions as determined by Smad2 phos-
phorylation and transnuclear location. As shown in Fig-the antiphosphorylated Smad2 (p-Smad2) antibody (Up-
state Biotechnology, Lake Placid, NY, USA) by both ure 1, immunocytochemistry demonstrated that it was
not until 24 hours after high glucose stimulation thatimmunohistochemistry and Western blotting. Detection
of phosphorylated Smad3 (p-Smad3) was subjected to TGF- Smad signaling became activated in all cell types
as evidenced by p-Smad2 nuclear translocation, whichimmunoprecipitation with the rabbit anti-Smad3 antibody

Fig. 2. Western blot or immunoprecipitation analyses demonstrate that high glucose induces Smad2 and Smad3 phosphorylation in tubular
epithelial cells (TECs), mesangial cells (MCs), vascular smooth muscle cells (VSMCs), and vascular endothelial cells (VECs) via the transforming
growth factor- (TGF-)-dependent mechanism. (A ) High glucose–induced Smad2 (by Western blotting) and Smad3 (by immunoprecipitation)
phosphorylation at 24 hours is blocked by a neutralizing anti-TGF- antibody (5 g/mL). (B ) High glucose (HG) (35 mmol/L), but not normal
glucose (NG) (5.5 mmol/L) in the presence or absence of anti-TGF- antibody (Ab) or d-mannitol control (35 mmol/L), induces Smad2 and
Smad3 phosphorylation at 24 hours in tubular epithelial cells and vascular smooth muscle cells. Note that high glucose–induced TGF-–dependent
Smad phosphorylation was blocked by the addition of a neutralizing TGF- antibody, but not by an isotype control rabbit immunoglobulin G
(IgG). (C ) Semiquantitative data (a ratio between p-Smad2/Smad2) from Western blot data in (A). Symbols are: () 0 minutes; ( ) 30 minutes;
( ) 12 hours; ( ) 24 hours; and ( ) 24 hours  antibody. (D ) Semiquantitative data (a ratio between p-Smad2/Smad2) from Western blot data
in (B). Symbols are: () normal glucose; ( ) high glucose; ( ) high glucose  IgG; ( ) high glucose  antibody; ( ) normal glucose  antibody;
and ( ) normal glucose  d-mannitol. Results represent the mean  SD for three independent experiments. *P  0.05; **P  0.01; ***P  0.001
compared to normal glucose aP  0.05; bP  0.01; cP  0.001 compared to high glucose and high glucose  control rabbit IgG treatment.
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was detected with the rabbit anti-p-Smad2 antibody (Fig. lation and collagen type I mRNA (by RT-PCR) and
protein (by Western blotting) expression in both tubular1A), accounting for up to 55% of cells (Fig. 1B). The
specificity of the antibody staining for p-Smad2 was con- epithelial cells and VSMCs (Figs. 2 B and D, 3 B and D,
and 4 B and D). It is also possible that high glucose–firmed by the control antibody staining in which no posi-
tive cells were found (not shown). In contrast, cells cul- induced activation of Smad signaling may be partially
attributed to its osmotic effect since mannitol seems totured at the normal level of glucose exhibited no increase
in Smad2 nuclear translocation (Fig. 1). Consistent with induce Smad phosphorylation above the background
level as shown in Figure 2B.these observations, Western blot analysis showed that
high glucose induced significant Smad2 phosphorylation
Overexpression of the inhibitory Smad7 blocks highin all cell types examined at 24 hours (Fig. 2). Similarly,
glucose–induced activation of Smad signaling andimmunoprecipitation also demonstrated that high glu-
collagen type I mRNA and protein expressioncose induced marked Smad3 phosphorylation at 24 hours
by both renal tubular epithelial cells and VSMCs (Fig. 2). The regulating role of Smad signaling in the high glu-
In contrast, no significant Smad2 and Smad3 phosphoryla- cose–induced fibrotic process was further demonstrated
tion at 24 hours was found in cells cultured under normal in a normal rat tubular epithelial cell line (NRK52E)
glucose or stimulated by d-mannitol (Fig. 2 B and D). that was stably transfected with a Dox-regulated Smad7
gene as previously described [21]. We have shown that
High glucose activates Smad signaling Smad7 expression is tightly controlled by the concentra-
and induces type I collagen synthesis via tions of Dox and that overexpression of Smad7 induced
the TGF-–dependent mechanism by Dox at 2 g/mL blocked TGF- (10 ng/mL)–induced
Next, we determined the mechanism by which high Smad2 activation and collagen matrix expression [21].
glucose activates TGF- Smad signaling. We postulate Similarly, Dox (2 g/mL)-induced overexpression of
that high glucose may activate Smad signaling and induce Smad7 prevented high glucose–induced Smad2 and
collagen synthesis via a TGF-–dependent mechanism. Smad3 nuclear translocation and phosphorylation (Fig. 5).
We tested this hypothesis by measuring the TGF- secre- This was associated with inhibition of collagen type I
tion within the medium and by adding a neutralizing mRNA and protein expression (Fig. 5 B and C).
TGF- antibody or an isotype control normal rabbit IgG
into the culture. Results in Figures 1 to 4 showed that
DISCUSSIONhigh glucose–induced Smad2 and Smad3 activation and
Hyperglycemia is thought to play a pivotal role incollagen I mRNA and protein expression in tubular epi-
the pathogenesis of diabetic nephropathy and vascularthelial cells, mesangial cells, VECs, and VSMCs were
complications by stimulating TGF- production [7–14].TGF- dependent. This is supported by the findings that
there was an increase in TGF- production in the me- The present study demonstrates that this involves activa-
tion of the Smad signaling pathway. Indeed, high glucosedium at 24 hours (122  7.8 pg/mL vs. 21  5.3 pg/mL
in normal glucose, P  0.01) and because the addition was shown to activate the Smad signaling pathway as
demonstrated by Smad2 and Smad3 phosphorylationof a neutralizing TGF- antibody, but not the isotype
control antibody, blocked high glucose–induced Smad 2 and nuclear translocation and this was associated with
the induction of collagen I mRNA and protein expres-nuclear translocation (Fig. 1) and Smad2 and Smad3
phosphorylation (Fig. 2), and collagen type I mRNA sion in tubular epithelial cells, mesangial cells, VECs,
and VSMCs. Activation of the Smad signaling pathwayand protein expression (Figs. 3 and 4). In contrast, cells
exposed to normal glucose in the presence or absence is TGF- dependent since this was associated with an
increased TGF- production at 24 hours and becauseof the neutralizing TGF- antibody or d-mannitol showed
no significant increase in Smad2 and Smad3 phosphory- high glucose activated the TGF- Smad signaling path-

Fig. 3. Reverse transcription-polymerase chain reaction (RT-PCR) demonstrates that high glucose (HG) induces collagen I mRNA expression
by tubular epithial cells (TECs), mesangial cells (MCs), vascular smooth muscle cells (VSMCs), and vascular endothelial cells (VECs) via a transforming
growth factor- (TGF-)-dependent mechanism. (A and B ) RT-PCR. (C ) Semiquantitative data [a ratio between mRNA/glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)] from (A). Symbols are: () normal glucose; ( ) normal glucose  d-mannitol; ( ) high glucose; and ( )
high glucose  antibody. (D ) Semiquantitative data (a ratio between mRNA/GAPDH) from (B). Note that collagen I mRNA is up-regulated in
all renal and vascular cells under high glucose (HG), but not in normal glucose (NG) in the presence or absence of the anti-TGF- antibody (Ab)
or d-mannitol (DM) conditions. Up-regulation of collagen I mRNA by high glucose is inhibited by the addition of a neutralizing TGF- antibody
(-TGF- antibody, 5g/mL), but not by the isotype control rabbit immunoglobulin G (IgG). Symbols are: () normal glucose; ( ) high glucose
( ) high glucose  IgG; ( ) high glucose  antibody; ( ) normal glucose  antibody; and ( ) normal glucose  d-mannitol. Results represent
the mean  SD for three independent experiments. *P  0.05; **P  0.01 compared to normal glucose; bP  0.01 compared to high glucose and
high glucose  control rabbit IgG treatment.
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way and collagen matrix expression was blocked by a back loop or the extracellular signal-related protein kinase-
neutralizing TGF- antibody. Furthermore, the finding (ERK)/p38 mitigen-activated protein (MAP) kinase
that overexpression of the inhibitory Smad7 blocked cross-talk pathways [18–20, 28, 29]. In addition, Smad7
high glucose–induced activation of TGF-–dependent binds to Smurf2 to form an E3 ubiquitin ligase that tar-
Smad signaling and collagen I mRNA and protein ex- gets the TGF- receptor for degradation [30]. We have
pression demonstrates that TGF- Smad signaling plays previously shown that TGF- is able to induce endoge-
a critical role in the regulation of renal and vascular nous Smad7 expression, but that the low grade of endog-
scarring under high glucose conditions. enous Smad7 expression is unable to overcome the fi-
TGF- is a secreted signaling molecule with fibrotic brogenic effect of TGF- on renal tubular epithelial cells
properties and regulates a diverse range of cellular re- associated with the activation of Smad2 [21]. However,
sponses, including proliferation, differentiation, migra- overexpression of Smad7 by gene transfer is able to in-
tion, and apoptosis [11–14]. There is increasing evidence hibit Smad2/3 activation in TGF-–dependent context,
that TGF- is a key mediator of fibrosis in both experi- including bleomycin-induced lung fibrosis and in a rat
mental and human kidney diseases, including diabetic obstructive nephropathy [31, 32]. In addition, we and
nephropathy and vascular disease [11–14]. Recent stud- other investigators have also demonstrated that over-
ies have suggested a pivotal role of Smads as intracellular expression of Smad7 blocks heme oxygenase-1 expres-
effector molecules of the TGF- family members sion and the fibrogenic effects of TGF- on renal tubular
[19, 20]. The involvement of Smads in TGF-–mediated epithelial cells and mesangial cells [21, 33, 34]. In the
renal fibrosis has been recently demonstrated by a num- present study, the negative regulatory role of Smad7
ber of studies. Indeed, Smad signaling has been shown in high glucose–induced renal and vascular fibrosis was
to play a role in TGF-–induced collagen matrix synthe- studied using an improved tetracycline-inducible system
sis in human mesangial cells and rat tubular cells [21–23], in which the expression of Smad7 transgene is under the
glomerular podocyte apoptosis during glomerulosclero- tight control of Dox [21]. Consistent with the known
sis [24], and tubular epithelial-myofibroblast transdiffer- role of Smad7, Dox-induced overexpression of Smad7
entiation [21]. Particularly, recent studies demonstrate blocked high-glucose–induced Smad activation as dem-
that Smad3 deficiency attenuates bleomycin-induced onstrated by marked inhibition of Smad2 and Smad3
pulmonary fibrosis in mice [25] and Smad3 overexpres- phosphorylation and transnuclear location and collagen
sion increases fibronectin promoter activity, an effect matrix synthesis. These data further emphasize that
that is enhanced by high glucose or treatment with Smad signaling plays a regulating role in hyperglycemia-
TGF-1 [26]. These findings implicate that Smad3 plays induced diabetic renal and vascular sclerosis.
a critical role in fibrosis. The present findings that high
glucose activates Smad2 and Smad3 and mediates colla-
CONCLUSIONgen matrix synthesis by stimulating TGF- production in
renal and vascular cells demonstrate that Smad signaling We demonstrate a key role for the TGF- Smad signal-
ing pathway in ECM production induced by high glucoseplays an important role in diabetic complications. These
in vitro findings presented in the current study support in a variety of cell types. We further show that high
glucose–activated Smad signaling is TGF- dependent.the potential role of Smad activation in diabetic db/db
mice and streptozotocin-induced diabetic mice [26, 27]. Importantly, the observation that inhibition of Smad sig-
naling by overexpression of Smad 7 can block high glu-A critical role for Smad signaling in diabetic renal and
vascular sclerosis was further demonstrated in the studies cose–mediated collagen matrix production indicates that
targeting the TGF- Smad signaling pathway may pro-involving inducible gene transfer of the inhibitory Smad7
in vitro. Smad7 is an endogenous inhibitor of Smad2/3 vide a novel therapeutic strategy for prevention and
treatment of diabetic complications.and blocks TGF- signaling via either the negative-feed-

Fig. 4. Western blot analysis demonstrates that high glucose (HG) induces collagen I protein synthesis by tubular epithelial cells (TECs), mesangial
cells (MCs), vascular smooth muscle cells (VSMCs), and vascular endothelial cells (VECs) via a transforming growth factor- (TGF-)–dependent
mechanism. (A ) High glucose–induced collagen I protein synthesis by renal and vascular cells is inhibited by the addition of a neutralizing TGF-
antibody (5g/mL). GAPDH is glyceraldehyde-3-phosphate dehydrogenase. (B ) Note that collagen I protein synthesis is up-regulated in tubular
epithelial cells and vascular smooth muscle cells under high glucose, but not in normal glucose (NG) in the presence or absence of the anti-TGF-
antibody (Ab) or d-mannitol (DM) conditions, and is blocked by the neutralizing TGF- antibody, but not by the isotype control rabbit
immunoglobulin G (IgG). (C ) Semiquantitative analysis (a ratio between collagen I and GAPDH proteins) for (A). Symbols are: () day 0; ( )
day 1; ( ) day 3; and ( ) day 3  antibody. (D ) Semiquantitative analysis (a ratio between collagen I and GAPDH proteins) for (B). Symbols
are: () normal glucose; ( ) high glucose ( ) high glucose  IgG; ( ) high glucose  antibody; ( ) normal glucose  antibody; and ( ) normal
glucose  d-mannitol. Results represent the mean  SD for four independent experiments. *P  0.05; **P  0.01; ***P  0.001 compared to
NG; aP  0.05; bP  0.001 compared to high glucose and high glucose  control rabbit IgG treatment.
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Fig. 5. Overexpression of Smad7 inhibits
high glucose–induced Smad2 activation and
collagen matrix synthesis in a stable Smad7
expressing tubular epithelial cell (TEC) line
(NRK52E). (A ) Immunocytochemistry dem-
onstrates that doxycycline (Dox) (2 g/mL)-
induced overexpression of Smad7 completely
blocks high glucose–induced phospho-Smad2
(p-Smad) and Smad3 transnuclear location
(black nuclei). Note that Smad3 protein is pri-
marily located within cytoplasm with negative
nuclear staining in both normal glucose (NG)
() and high glucose  Dox ( ), but it trans-
locates into nuclei when becomes activated at
24 hours after high glucose () stimulation.
(B ) Western blot, immunoprecipitation, and
reverse transcription-polymerase chain reac-
tion (RT-PCR) analyses demonstrate that Dox
(2 g/mL)-induced overexpression of Smad7
results in substantial inhibition of Smad2 (by
Western blotting) and Smad3 (by immunopre-
cipitation) phosphorylation and collagen I
mRNA and protein expression. Values shown
in (B) are a ratio between p-Smad2/Smad2 or
collagen I mRNA (protein)/glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA
(protein). Symbols are: () normal glucose;
( ) normal glucose  Dox; ( ) high glucose;
( ) high glucose  Dox. Results represent
four independent experiments and are ex-
pressed as the mean SD. *P 0.05; ***P
0.001 compared to NG. bP  0.01; cP  0.001
compared to high glucose without Dox treat-
ment. Magnification 250.
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